We wish to inform you that the Board of Directors of Asarfi Hospital Limited (the Company), at its meeting held today i.e. on 08TH May, 2025 has considered and approved the audited Standalone ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 2.1 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Asarfi Hospital Limited approved audited standalone and consolidated financial results for Q4 and full year ended 31st March 2025 on 8th May 2025. Standalone revenue from operations grew sharply to Rs 12,056.57 lakhs from Rs 8,440.04 lakhs in FY24 (about 42% growth), while net profit jumped to Rs 1,097.97 lakhs from Rs 421.22 lakhs (over 160% growth), translating to EPS of Rs 5.58 vs Rs 2.33. Q4 FY25 standalone PAT was Rs 382.86 lakhs against a loss of Rs 15.94 lakhs in Q4 FY24. The statutory auditor R.K. Thakkar & Co issued an unqualified opinion on both sets of results. Long-term borrowings nearly doubled to Rs 3,382.93 lakhs, and trade receivables rose sharply, while operating cash flow turned negative at Rs (384.26) lakhs despite strong profit growth.
Strong top-line and bottom-line growth is positive for shareholders, but the surge in long-term debt (up ~94% YoY), rising receivables, and negative operating cash flow warrant close attention as they suggest working capital strain despite higher profits.